European Crohn´s and Colitis Organisation - ECCO - Submit an abstract
Media Kit 2020 2020
PDF) P374 Non-alcoholic fatty liver disease in inflammatory bowel disease: Prevalence and risk factors
Frontiers | Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease
Media Kit 2020 2020
Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis - The Lancet Gastroenterology & Hepatology
PDF) European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's Disease
European Crohn´s and Colitis Organisation - ECCO - Call for abstracts for the 18th Congress of ECCO
PDF) P659 FMT as a treatment for IBD: A national survey of gastroenterologists in the UK
PDF) P320 Utility of a semi-quantitative rapid test in diagnosis of ulcerative colitis
PDF) ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
Early life exposures and the risk of inflammatory bowel disease: Systematic review and meta-analyses - eClinicalMedicine
PDF) P451 Short-and long-term effectiveness of ustekinumab in patients with Crohn's disease: real-world data from a German IBD cohort
Inflammatory Bowel Diseases
D-ECCO (@D_ECCO_IBD) / X
Accepted Manuscript
Journal of Crohn's and Colitis | Oxford Academic
PDF) DOP028 Second N-ECCO Consensus Statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis
JCM | Free Full-Text | The Promise of Single-Cell RNA Sequencing to Redefine the Understanding of Crohn’s Disease Fibrosis Mechanisms
All abstracts for the ICOS Science Conference 2020 | ICOS
ESOI - European Society of Oncologic Imaging - We are very proud to announce that ESOI is now the newest member of ECCO - the European CanCer Organisation! ECCO's vision is to
Ecco Store Stock Photo - Download Image Now - Boot, Boutique, Building Entrance - iStock
Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches
